The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy - A Canadian study

Seizure

Volumn 11, Issue 1, 2002, Pages 6-15

  Baker, Gus A ^a   Currie, Natalie G T ^b   Light, Margaret J ^b   Schneiderman, Jack H ^c  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Janssen Ortho Inc   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epilepsy; Quality of life; Seizure; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; TOPIRAMATE;

ADULT; AGED; AMNESIA; ARTICLE; CANADA; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FEMALE; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SEIZURE; SOMNOLENCE; STATISTICAL ANALYSIS; VERTIGO;

EID: 0036191291     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1053/seiz.2001.0581     Document Type: Article

References (40)

1. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons
2. The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons
3. Topiramate selectively blocks kainate currents in cultured hippocampal neurons
4. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages
5. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages
6. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy
7. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy
8. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures
9. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset epilepsy
10. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children
11. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures
12. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome
13. A pilot study of topiramate in the treatment of infantile spasms
14. The new antiepileptic drugs: A systematic review of their efficacy and tolerability
15. The contribution of the measurement of seizure severity to quality of life research
16. Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugs
17. The initial development of a health-related quality of life model as an outcome measure in epilepsy
18. Quality of life and regulatory issues
19. Development of the quality of life in epilepsy inventory
20. Practical aspects of the use of topiramate in patients with epilepsy
21. Commission on classification and terminology of the international league against epilepsy, proposal for revised clinical and electroncephalographic classification of epileptic seizures
22. The development of a seizure severity scale as an outcome measure in epilepsy
23. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
24. Liverpool seizure severity scale revisited
25. Validity-norm-based interpretation
26. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy
27. Topiramate in intractable childhood onset epilepsy - A cautionary note
28. Hidden bias in research design
29. Antiepileptic drugs as a cause of worsening seizures
30. Aggravation of focal epileptic seizures by antiepileptic drugs
31. Outcomes of add-on treatment with lamotrigine in partial epilepsy
32. Quality of life of people with epilepsy: A European study
33. The SF-36 as a health status measure for epilepsy: A psychometric assessment
34. A health-related quality of life instrument for patients evaluated for epilepsy surgery
35. Topiramate: Clinical profile in epilepsy
36. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference (EILAT IV)
37. Medical management of epilepsy in adults
38. Weight gain during treatment with valproate
39. Weight gain with valproate or carbamazepine - A reappraisal